Literature DB >> 23685282

Association of genetic polymorphisms in ADH and ALDH2 with risk of coronary artery disease and myocardial infarction: a meta-analysis.

Hongguang Han1, Huishan Wang, Zongtao Yin, Hui Jiang, Minhua Fang, Jingsong Han.   

Abstract

Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) are the major enzymes responsible for alcohol metabolism in humans. Emerging evidences have shown that functional polymorphisms in ADH and ALDH genes might play a critical role in increasing coronary artery disease (CAD) and myocardial infarction (MI) risks; however, individually published studies showed inconclusive results. The aim of this meta-analysis is to evaluate the associations between the genetic polymorphisms of ADH and ALDH genes with susceptibility to CAD and MI. A literature search was conducted on PubMed, Embase, Web of Science and Chinese BioMedical databases from inception through December 1st, 2012. Crude relative risks (RRs) with 95% confidence intervals (CIs) were calculated. Twelve case-control studies were included with a total of 9616 subjects, including 2053 CAD patients, 1436 MI patients, and 6127 healthy controls. Meta-analysis showed that mutant genotypes (GA+AA) of the rs671 polymorphism in the ALDH2 gene were associated with increased risk of both CAD and MI (CAD: RR=1.20, 95%CI: 1.03-1.40, P=0.021; MI: RR=1.32, 95%CI: 1.11-1.57, P=0.002). However, there were no significant associations of ADH genetic polymorphisms to CAD and MI risks (CAD: RR=0.92, 95%CI: 0.73-1.15, P=0.445; MI: RR=0.93, 95%CI: 0.84-1.03, P=0.148). In conclusion, this meta-analysis provides strong evidence that ALDH2 rs671 polymorphism may be associated with increased risks of CAD and MI. However, further studies are still needed to accurately determine whether ADH genetic polymorphisms are associated with susceptibility to CAD and MI.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  95% confidence interval; 95%CI; ADH; ALDH; Alcohol dehydrogenase; Aldehyde dehydrogenase; CAD; Coronary artery disease; HWE; Hardy–Weinberg equilibrium; MI; Meta-analysis; Myocardial infarction; RR; SNP; Single nucleotide polymorphism; alcohol dehydrogenase; aldehyde dehydrogenase; coronary artery disease; myocardial infarction; relative risk; single nucleotide polymorphisms

Mesh:

Substances:

Year:  2013        PMID: 23685282     DOI: 10.1016/j.gene.2013.05.002

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  19 in total

1.  Not just correlative: a new pathway defines how an ALDH2 SNP contributes to atherosclerosis.

Authors:  Andrew A Gibb; John W Elrod
Journal:  J Clin Invest       Date:  2018-12-03       Impact factor: 14.808

2.  Hepatic injury and inflammation alter ethanol metabolism and drinking behavior.

Authors:  Tianyi Ren; Bryan Mackowiak; Yuhong Lin; Yanhang Gao; Junqi Niu; Bin Gao
Journal:  Food Chem Toxicol       Date:  2019-12-21       Impact factor: 6.023

Review 3.  Genetic instrumental variable analysis: time to call mendelian randomization what it is. The example of alcohol and cardiovascular disease.

Authors:  Kenneth J Mukamal; Meir J Stampfer; Eric B Rimm
Journal:  Eur J Epidemiol       Date:  2019-11-24       Impact factor: 8.082

4.  The Moderate Alcohol and Cardiovascular Health Trial (MACH15): Design and methods for a randomized trial of moderate alcohol consumption and cardiometabolic risk.

Authors:  Donna Spiegelman; Laura C Lovato; Polyna Khudyakov; Trine L Wilkens; Clement A Adebamowo; Sally N Adebamowo; Lawrence J Appel; Joline Wj Beulens; Janelle W Coughlin; Lars Ove Dragsted; Howard J Edenberg; Jane N Eriksen; Ramon Estruch; Diederick E Grobbee; Pablo E Gulayin; Vilma Irazola; John H Krystal; Mariana Lazo; Margaret M Murray; Eric B Rimm; Ilse C Schrieks; Jeff D Williamson; Kenneth J Mukamal
Journal:  Eur J Prev Cardiol       Date:  2020-04-06       Impact factor: 7.804

5.  Activation of aldehyde dehydrogenase 2 slows down the progression of atherosclerosis via attenuation of ER stress and apoptosis in smooth muscle cells.

Authors:  Mei-Yan Yang; Ya-Bin Wang; Bo Han; Bo Yang; Yu-Wei Qiang; Yan Zhang; Zhao Wang; Xu Huang; Jie Liu; Yun-Dai Chen; Jun Ren; Feng Cao; Yong Xu
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

Review 6.  Alcohol and Immediate Risk of Cardiovascular Events: A Systematic Review and Dose-Response Meta-Analysis.

Authors:  Elizabeth Mostofsky; Harpreet S Chahal; Kenneth J Mukamal; Eric B Rimm; Murray A Mittleman
Journal:  Circulation       Date:  2016-03-08       Impact factor: 29.690

7.  An association between serum γ-glutamyltransferase and proteinuria in drinkers and non-drinkers: a Japanese nationwide cross-sectional survey.

Authors:  Toshihiro Ishigami; Ryohei Yamamoto; Yasuyuki Nagasawa; Yoshitaka Isaka; Hiromi Rakugi; Kunitoshi Iseki; Kunihiro Yamagata; Kazuhiko Tsuruya; Hideaki Yoshida; Shouichi Fujimoto; Koichi Asahi; Issei Kurahashi; Yasuo Ohashi; Toshiki Moriyama; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2014-02-04       Impact factor: 2.801

8.  Acetaldehyde dehydrogenase 2 interactions with LDLR and AMPK regulate foam cell formation.

Authors:  Shanshan Zhong; Luxiao Li; Yu-Lei Zhang; Lili Zhang; Jianhong Lu; Shuyuan Guo; Ningning Liang; Jing Ge; Mingjiang Zhu; Yongzhen Tao; Yun-Cheng Wu; Huiyong Yin
Journal:  J Clin Invest       Date:  2018-12-03       Impact factor: 14.808

Review 9.  Targeting mitochondrial dysfunction and oxidative stress in heart failure: Challenges and opportunities.

Authors:  Ligia Akemi Kiyuna; Rudá Prestes E Albuquerque; Che-Hong Chen; Daria Mochly-Rosen; Julio Cesar Batista Ferreira
Journal:  Free Radic Biol Med       Date:  2018-09-15       Impact factor: 7.376

10.  Synergistic association between two alcohol metabolism relevant genes and coronary artery disease among Chinese hypertensive patients.

Authors:  Yuefei Wang; Fengxia Du; Hongye Zhao; Xiaohong Yu; Jun Liu; Yu Xiao; Changzhu Lu; Xue Li; Yanli Wang; Bin Wang; Wenquan Niu
Journal:  PLoS One       Date:  2014-07-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.